Jade Biosciences Inc. in Waltham, MA, launched on 1 August with the closing of an $80m financing to fund its development of best-in-class targeted therapies for autoimmune diseases. The company follows Apogee Therapeutics, Inc., Spyre Therapeutics and Oruka Therapeutics as the fourth company to emerge with assets discovered and developed by Paragon Therapeutics, Inc. (Also see "Oruka Aiming At AbbVie, UCB In Psoriatic Indications" - Scrip, 3 April, 2024.) Jade launches with a portfolio of preclinical Paragon assets and with chief scientific officer Andrew King, who previously was CSO of kidney disease drug developer Chinook Therapeutics, Inc., which Novartis bought for $3.2bn up front last year. (Also see "Novartis Aims To Fly High In Kidney Disease With Chinook Buy" - Scrip, 12 June, 2023.)

Finance Watch: Fresh Cash For Life Science Firms From venBio, Symbiotic

Shinobi Doubles Cash With Japanese Grant

More from Financing

More from Business